The Role of Laryngopharyngeal Reflux in IPF
1 other identifier
observational
60
1 country
1
Brief Summary
The primary objective of this study is to show that the Supraglottic Index (SGI) is an easily-collected index that accurately identifies the presence and severity of laryngopharyngeal reflux (LPF) in idiopathic pulmonary fibrosis (IPF).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 23, 2018
CompletedFirst Posted
Study publicly available on registry
February 1, 2018
CompletedStudy Start
First participant enrolled
August 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
ExpectedNovember 14, 2024
November 1, 2024
7.3 years
January 23, 2018
November 12, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
The supraglottic index (SGI) quantifies laryngopharyngeal reflux (LPF) and is associated with severity of pulmonary fibrosis.
Correlation between the supraglottic index and forced vital capacity. The supraglottic index is an index derived by assigning scores for edema and erythema of five supraglottic structures (epiglottis, false cords, arytenoids, posterior commissure, piriform recess) as viewed through a fiber-optic scope. Scores range from 0-22, with higher scores indicating more severe LPR.
6 months
Eligibility Criteria
ILD clinic
You may qualify if:
- Diagnosis of IPF
- Age 40-95
- Able to read, speak, and understand English
- If subjects are currently taking medication for reflux or GERD, they much be on a stable does for at least 4 weeks prior to consent.
You may not qualify if:
- Pregnant females
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Jewish Health
Denver, Colorado, 80206, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Matthew Koslow, DO
National Jewish Health
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
January 23, 2018
First Posted
February 1, 2018
Study Start
August 1, 2018
Primary Completion
December 1, 2025
Study Completion (Estimated)
December 1, 2026
Last Updated
November 14, 2024
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will not share
No IPD will be available to other researchers.